Trevena (NASDAQ:TRVN) & Qualigen Therapeutics (NASDAQ:AIXC) Critical Comparison

Trevena (NASDAQ:TRVN) and Qualigen Therapeutics (NASDAQ:AIXC) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability.

Insider and Institutional Ownership

13.6% of Trevena shares are owned by institutional investors. Comparatively, 3.2% of Qualigen Therapeutics shares are owned by institutional investors. 2.7% of Trevena shares are owned by insiders. Comparatively, 1.2% of Qualigen Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Trevena and Qualigen Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Trevena	N/A	N/A	-119.55%
Qualigen Therapeutics	N/A	-771.52%	-79.52%

Analyst Ratings

This is a summary of current ratings and price targets for Trevena and Qualigen Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trevena	0	0	0	0	0.00
Qualigen Therapeutics	1	0	0	0	1.00

Volatility & Risk

Trevena has a beta of 0.31, meaning that its stock price is 69% less volatile than the S&P 500. Comparatively, Qualigen Therapeutics has a beta of 0.49, meaning that its stock price is 51% less volatile than the S&P 500.

Valuation & Earnings

This table compares Trevena and Qualigen Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trevena	$443,000.00	0.02	-$40.29 million	($47.04)	-0.00
Qualigen Therapeutics	N/A	N/A	-$16.97 million	($6.47)	-0.16

Qualigen Therapeutics has lower revenue, but higher earnings than Trevena. Qualigen Therapeutics is trading at a lower price-to-earnings ratio than Trevena, indicating that it is currently the more affordable of the two stocks.

About Trevena

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania.

About Qualigen Therapeutics

Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient’s blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.